Evidence map›Paper›PMID 29411182›Full record

ArticleClinical rheumatology2018

Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE).

Florenzo Iannone, Leonardo Santo, Romano Bucci, Angelo Semeraro, Giorgio Carlino, Franco Paoletti, Laura Quarta, Pierfrancesco Leucci, Carmelo Zuccaro, Antonio Marsico and 6 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Monotherapy or combination therapy in PsA: current aspects.Therapeutic advances in musculoskeletal disease · 2024
    Review
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Ustekinumab in psoriatic arthritis and related phenotypes.Therapeutic advances in chronic disease · 2018
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Florenzo IannoneDepartment of Emergency and Organ Transplantation-Rheumatology Unit, Policlinico, University of Bari, Piazza G. Cesare 11, 70124, Bari, Italy. florenzo.iannone@uniba.it.ORCID http://orcid.org/0000-0003-0474-5344
Leonardo SantoRheumatology Service, DSS4 Barletta ASL BT Andria, Barletta, Italy.
Romano BucciRheumatology Hospital Unit, A.O.U. "OO.RR. Foggia", Foggia, Italy.
Angelo SemeraroUO of Rheumatology, ASL Taranto, Taranto, Italy.
Giorgio CarlinoRheumatology Service, ASL Lecce-DSS Casarano and Gallipoli (LE), Casarano, Italy.
Franco PaolettiAsrem Rheumatology Service, SF Caracciolo Hospital, Agnone, IS, Italy.
Laura QuartaU.O. of Rheumatology, "V.Fazzi" Hospital, Lecce, Italy.
Pierfrancesco LeucciRheumatology Service, ASL Lecce DSS Maglie, Maglie, Italy.
Carmelo ZuccaroHospital Outpatient Clinic of Rheumatology, ASL BR, Brindisi, Italy.
Antonio MarsicoUO of Rheumatology, ASL Taranto, Taranto, Italy.
Crescenzio SciosciaDepartment of Emergency and Organ Transplantation-Rheumatology Unit, Policlinico, University of Bari, Piazza G. Cesare 11, 70124, Bari, Italy.
Francesca D'OnofrioUOC Reumatologia Universitaria, University of Foggia, Foggia, Italy.
Daniela MazzottaHospital Outpatient Clinic of Rheumatology, ASL BR, Brindisi, Italy.
Maurizio MuratoreU.O. of Rheumatology, "V.Fazzi" Hospital, Lecce, Italy.
Francesco Paolo CantatoreUOC Reumatologia Universitaria, University of Foggia, Foggia, Italy.
Giovanni LapadulaDepartment of Emergency and Organ Transplantation-Rheumatology Unit, Policlinico, University of Bari, Piazza G. Cesare 11, 70124, Bari, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aims to evaluate the drug survival and effectiveness of ustekinumab in psoriatic arthritis (PsA) patients naïve to biologics or inadequate responders to tumor necrosis factor (TNF-IR) inhibitors in real life. PsA patients starting ustekinumab were enrolled from 2014 to 2016. Joint involvement, peripheral or axial, Psoriatic Area Severity Index, Disease Activity Psoriatic Arthritis (DAPSA), Lee Enthesitis Index, Health Assessment Questionnaire, body mass index, comorbidities, co-therapies, mechanism of action, and causes of discontinuation of prior TNFi were collected at baseline, and 6 and 12 months. Twelve-month drug survival was evaluated by Kaplan-Meier curves. Hazard ratios (HRs) of drug discontinuation adjusted for baseline factors were estimated by multiple Cox regression analysis. Percentages of DAPSA-based remission, as crude value and adjusted for drug retention (LUNDEX index), were compared by χ

Indexed as

AdultAgedAntirheumatic AgentsArthritis, PsoriaticFemaleHumansMaleMiddle AgedRegistriesSeverity of Illness IndexTreatment OutcomeUstekinumabAntirheumatic AgentsUstekinumabAxial psoriatic arthritisEnthesitisPeripheral psoriatic arthritisUstekinumab

Identifiers

PMID29411182

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.